Analysis of the replication kinetics of the chimerivax™-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction

American Journal of Tropical Medicine and Hygiene

Volumn 70, Issue 1, 2004, Pages 89-97

  Johnson, Barbara W ^a   Chambers, Trudy V ^a   Crabtree, Mary B ^a   Guirakhoo, Farshad ^b   Monath, Thomas P ^b   Miller, Barry R ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b Acambis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIVAX; DENGUE VACCINE; LIVE VACCINE; TETRAVALENT DENGUE VIRUS VACCINE; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE; VIRUS DNA; VIRUS VACCINE; WEST NILE VACCINE;

AEDES AEGYPTI; AEDES ALBOPICTUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CELL LINE; CHIMERA; DENGUE; DENGUE VIRUS; ENVELOPE GENE; KINETICS; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROTYPE; VIREMIA; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; YELLOW FEVER FLAVIVIRUS; AEDES; ANIMAL; CHEMISTRY; DISEASE CARRIER; DNA SEQUENCE; GENETIC REASSORTMENT; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; VIROLOGY;

AEDES AEGYPTI; AEDES ALBOPICTUS; ANIMALIA; DENGUE VIRUS; FLAVIVIRUS; RNA VIRUSES; YELLOW FEVER VIRUS;

AEDES; ANIMALS; CELL LINE; DENGUE VIRUS; DNA, VIRAL; INSECT VECTORS; KINETICS; POLYMERASE CHAIN REACTION; REASSORTANT VIRUSES; SEQUENCE ANALYSIS, DNA; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS REPLICATION; WEST NILE VIRUS VACCINES;

EID: 1542349168     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2004.70.89     Document Type: Article

References (40)

1. Gubler DJ, 1988. Dengue. Monath TP, ed. The Arboviruses: Epidemiology and Ecology. Boca Raton, FL: CRC Press, 223-260.
2. Gubler DJ, 1998. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11: 480-496.
3. Koraka P, Zeller H, Niedrig M, Osterhaus AD, Groen J, 2002. Reactivity of serum samples from patients with a flavivirus infection measured by immunofluorescence assay and ELISA. Microbes Infect 4: 1209-1215.
4. Gubler DJ, 1998. The global pandemic of dengue/dengue haemorrhagic fever: current status and prospects for the future. Ann Acad Med Singapore 27: 227-234.
5. Division of Disease Prevention and Control CDP, 1997. Reemergence of dengue in the Americas. Epidemiol Bull 18: 1-6.
6. Gubler DJ, 1998. Epidemic dengue and dengue hemorrhagic fever: a global public health problem in the 21st century. Scheld W, Armstrong D, Hughes J, eds. Emerging Infections. Washington, DC: American Society for Microbiology Press, 1-14.
7. Monath TP, 1994. Dengue: the risk to developed and developing countries. Proc Natl Acad Sci USA 91: 2395-2400.
8. Rothman AL, Ennis FA, 1999. Immunopathogenesis of dengue hemorrhagic fever. Virology 257: 1-6.
9. Porterfield JS, 1986. Antibody-dependent enhancement of viral infectivity. Adv Virus Res 31: 335-355.
10. Tirado SM, Yoon KJ, 2003. Antibody-dependent enhancement of virus infection and disease. Viral Immunol 16: 69-86.
11. Gubler DJ, Clark GG, 1995. Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis 1: 55-57.
12. Chambers TJ, Nestorowicz A, Mason PW, Rice CM, 1999. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 73: 3095-3101.
13. Guirakhoo F, Zhang ZX, Chambers TJ, Delagrave S, Arroyo J, Barrett AD, Monath TP, 1999. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257: 363-372.
14. Monath TP, Soike K, Levenbook I, Zhang ZX, Arroyo J, Delagrave S, Myers G, Barrett AD, Shope RE, Ratterree M, Chambers TJ, Guirakhoo F, 1999. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 17: 1869-1882.
15. Guirakhoo R, Weltzin R, Chambers T, Zhang Z-X, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath T, 2000. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74: 5477-5485.
16. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP, 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75: 7290-7304.
17. Arroyo J, Miller CA, Catalan J, Monath TP, 2001. Yellow fever vector live-virus vaccines. West Nile virus vaccine development. Trends Mol Med 7: 350-354.
18. Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ, 2001. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol 75: 934-942.
19. Monath TP, 2001. Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci 951: 1-12.
20. Monath TP, Arroyo J, Miller C, Guirakhoo F, 2001. West Nile virus vaccine. Curr Drug Targets Infect Disord 1: 37-50.
21. Monath TP, 1991. Yellow fever: Victor, Victoria? conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. Am J Trop Med Hyg 45: 1-43.
22. Marianneau P, Georges-Courbot M, Deubel V, 2001. Rarity of adverse effects after 17D yellow-fever vaccination. Lancet 358: 84-85.
23. Whitman L, 1939. Failure of Aedes aegypti to transmit yellow fever cultured virus (17D). Am J Trop Med 19: 19-26.
24. Bhatt TR, Crabtree MB, Guirakhoo F, Monath TP, Miller BR, 2000. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg 62: 480-484.
25. Johnson BW, Chambers TV, Crabtree MB, Bhatt TR, Guirakhoo F, Monath TP, Miller BR, 2002. Growth characteristics of ChimeriVax-DEN-2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am J Trop Med Hyg 67: 260-265.
26. Johnson BW, Chambers TV, Crabtree MB, Arroyo J, Monath TP, Miller BR, 2003. Growth characteristics of the veterinary vaccine candidate ChimeriVax™-West Nile (WN) virus in Aedes and Culex mosquitoes. Med Vet Entomol 17: 235-243.
27. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Draper K, Monath TP, 2002. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298: 146-159.
28. Miller BR, Mitchell CJ, Ballinger ME, 1989. Replication, tissue tropisms and transmission of yellow fever virus in Aedes albopictus. Trans R Soc Trop Med Hyg 83: 252-255.
29. Lanciotti RS, Kerst AJ, Nasci RS, Godsey MS, Mitchell CJ, Savage HM, Komar N, Panella NA, Allen BC, Volpe KE, Davis BS, Roehrig JT, 2000. Rapid detection of West Nile virus from human clinical specimens, field-collected mosquitoes, and avian samples by a TaqMan reverse transcriptase-PCR assay. J Clin Microbiol 38: 4066-4071.
30. Rosen L, Roseboom LE, Gubler DJ, Lien JC, Chaniotis BN, 1985. Comparative susceptibility of mosquito species and strains to oral and parenteral infection with dengue and Japanese encephalitis viruses. Am J Trop Med Hyg 34: 603-615.
31. Miller BR, 1987. Increased yellow fever virus infection and dissemination rates in Aedes aegypti mosquitoes orally exposed to freshly grown virus. Trans R Soc Trop Med Hyg 81: 1011-1012.
32. Weaver SC, Lorenz LH, Scott TW, 1993. Distribution of western equine encephalomyelitis virus in the alimentary tract of Culex tarsalis (Diptera: Culicidae) following natural and artificial blood meals. J Med Entomol 30: 391-397.
33. Turell MJ, Spring AR, Miller MK, Cannon CE, 2002. Effect of holding conditions on the detection of West Nile viral RNA by reverse transcriptase-polymerase chain reaction from mosquito (Diptera: Culicidae) pools. J Med Entomol 39: 1-3.
34. Kramer LD, Chiles RE, Do TD, Fallah HM, 2001. Detection of St. Louis encephalitis and western equine encephalomyelitis RNA in mosquitoes tested without maintenance of a cold chain. J Am Mosq Control Assoc 17: 213-215.
35. Armstrong PM, Rico-Hesse R, 2001. Differential susceptibility of Aedes aegypti to infection by the American and Southeast Asian genotypes of dengue type 2 virus. Vector Borne Zoonotic Dis 1: 159-168.
36. Gubler DJ, Rosen L, 1976. A simple technique for demonstrating transmission of dengue virus by mosquitoes without the use of vertebrate hosts. Am J Trop Med Hyg 25: 146-150.
37. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS, 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65: 405-413.
38. Gubler DJ, Suharyono W, Tan R, Abidin M, Sie A, 1981. Viraemia in patients with naturally acquired dengue infection. Bull World Health Organ 59: 623-630.
39. Chambers TJ, Hahn CS, Galler R, Rice CM, 1990. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44: 649-688.
40. Lindenbach B, Rice C, 2001. Flaviviridae: the viruses and their replication. Knipe D, Howley P, eds. Fields Virology. Philadelphia: Lipincott William and Wilkins, 991-1043.